Does Hikma’s Vascepa Litigation Dismissal Suggest Safety For Skinny Labels?
GSK-Teva Rulings Had Been Seen As An Existential Threat To Indication Carve-Outs
An induced-infringement attack on Hikma’s skinny-label generic version of Vascepa had been cited as evidence of the potential harm that would be caused by controversial rulings in separate litigation involving GSK and Teva. However, these fears may now appear overstated after the claim against Hikma was dismissed.
